Brazil Mouth Ulcer Therapeutics Market Analysis

Brazil Mouth Ulcer Therapeutics Market Executive Summary

The Brazil Mouth Ulcer Therapeutics Market is at around $38 Mn in 2023 and is projected to reach $53.1 Mn in 2030, exhibiting a CAGR of 4.9% during the forecast period 2023-2030.

Mouth ulcers, also known as canker sores, are classified into three main types: minor aphthous ulcers which are the most common small oval lesions, major aphthous ulcers that are larger and deeper causing more pain, and herpetiform ulcers which start as multiple small ulcers that can merge into one large ulcer. While the exact cause is unknown, several risk factors have been identified including stress, anxiety, hormonal changes, nutritional deficiencies (iron, vitamin B12, folic acid, zinc), certain medical conditions like celiac disease, Crohn's disease, and HIV/AIDS, as well as trauma from dental work, braces, or ill-fitting dentures. In most cases, mouth ulcers are self-limiting and resolve within 1-2 weeks without treatment. However, complications can arise such as secondary infection, severe pain affecting one's ability to eat or drink properly, and potential scarring in cases of severe recurrent ulcers. Prevention involves reducing stress, avoiding potential food triggers like citrus fruits, nuts, and chips, using soft-bristled toothbrushes and waxed dental floss, and replacing toothpaste if it seems to be a trigger. Treatment involves symptomatic relief with topical gels containing anesthetics, antiseptics, and antibiotics, as well as supportive care with multivitamins or vitamin supplements, antipyretics, and antibiotics. Medications include antibiotics, oral painkillers, oral steroids, antiseptics, chlorhexidine gluconate mouthwash, and sucralfate. Home care includes good oral hygiene, avoiding trigger foods, warm saline gargles, ice packs, and a balanced diet. Medical attention is necessary if the ulcers fail to heal within a week or two, are unusual, spreading, or large, or if there is severe pain, fever, or difficulty while chewing, talking, or swallowing.

The prevalence rate of Mucosal lesions was found in 22.4% of population. The most prevalent lesions were fistulae (6.2%) and traumatic ulcers (4.48%). The market therefore is driven by significant factors like the increasing prevalence rate mouth ulcers, growing demand for instant relief solutions, and healthcare advancements, however, factors such as limited accessibility, and availability of substitute treatments limit market growth.

The industry is primarily dominated by players such as Eurofarma, EMS Pharma, ACHE and Sanofi among others.

Market Dynamics

Market Growth Drivers

High Prevalence: Mouth ulcers, particularly in the lip, oral cavity, and oropharynx, are a significant health concern in Brazil. The high incidence of these types of cancer drives a substantial demand for effective treatment options. With a prevalence rate of around 22%, the need for innovative and accessible treatments is pressing.

Advancements in Healthcare: Advancements in healthcare, including the development of new treatments and therapies, contribute to the growth of the mouth cancer treatment market. Improved diagnostic techniques and innovative treatment approaches offer better outcomes for patients. The availability of these advancements drives demand and adoption within the market.

Increased Demand for Instant Relief: Mouth cancer patients often experience pain and discomfort, leading to a growing demand for instant relief. Pharmaceutical treatments that can alleviate these symptoms quickly are highly sought after. This demand for immediate relief drives the adoption of effective pharmaceutical treatments for mouth cancer.

Market Restraints

Competition from Home Remedies: The availability of home remedies and over-the-counter medications provides more affordable alternatives to pharmaceutical treatments. These alternatives can be appealing to individuals with limited financial resources or those seeking more natural approaches. The competition from these alternatives constrains the growth of the pharmaceutical mouth cancer treatment market.

Limited Accessibility to Pharmaceuticals: In some areas of Brazil, access to pharmaceutical treatments for mouth cancer may be limited due to cost or availability issues. Factors such as geographical location, healthcare infrastructure, and affordability can restrict access to these treatments. This limited accessibility can hinder market growth and limit the reach of effective pharmaceutical treatments.

Regulatory Landscape and Reimbursement Scenario

ANVISA is an autarchy (semi-autonomous government agency) linked to the Brazilian Ministry of Health and part of the Brazilian National Health System (SUS). It serves as the coordinator of the Brazilian Health Regulatory System (SNVS) and has a presence throughout the national territory. ANVISA is responsible for the approval and supervision of food, cosmetics, tobacco, pharmaceuticals, health services, and medical devices, among others. It functions as the Brazilian counterpart to the U.S. Food and Drug Administration (FDA), regulating all health-related products. While some low-risk products may be exempt, it is mandatory to have a local importer or distributor for product liability purposes. Foreign companies are recommended to have technical staff and replacement parts available locally for customer support. The Brazilian healthcare market is price-driven, with domestically manufactured products having a distinct price advantage. Meeting quality and regulatory standards is important for products to be approved by ANVISA. Companies must meet all sanitary registration requirements set by ANVISA to sell products to the government. Foreign companies should consider cost-saving measures and highlight the benefits of new technologies in their marketing and promotional materials to compete in the Brazilian market.

Competitive Landscape

Key Players

Here are some of the major key players in the Brazil Mouth Ulcers Therapeutics Market:

• Eurofarma
• EMS Pharma
• ACHE
• Sanofi
• Teva pharmaceuticals
• Merck & Co
• Taro Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• BLISTEX, INC.
• GlaxoSmithKline plc.